Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2/3 study of Thykamine in pediatric patient population with mild-to-moderate atopic dermatitis

Next Previous
Trial Profile

A phase 2/3 study of Thykamine in pediatric patient population with mild-to-moderate atopic dermatitis

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 28 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Thykamine (Primary)
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms Pediatric AD clinical study

Most Recent Events

  • 22 Jul 2026 According to a Devonian media release, the trial employs a seamless adaptive Phase II/III design, incorporating an interim analysis following completion of Phase II to allow a seamless transition into the confirmatory Phase III portion of the program.
  • 21 Jul 2026 According to a Devonian media release, Health Canada has authorized the Company's Clinical Trial Application (CTA) to initiate its Phase II/III clinical study evaluating PUR 0110 (Thykamine) cream for the treatment of mild-to-moderate atopic dermatitis (AD) in pediatric patients.
  • 12 Dec 2025 According to a Devonian media release, design for Thykamine Phase 2/3 clinical study in pediatric Atopic Dermatitis is complete based on the positive results of the phase 2 in an adult population. The study is ready to be initiated following approval by regulatory agencies.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top